Ligand Pharmaceuticals Q2 revenue rises on royalty growth

Ligand Pharmaceuticals Incorporated

06/08/2026 12:26

Overview
Biopharma royalty aggregator's Q2 revenue rose 34% yr/yr, driven by 32% royalty revenue growth
Q2 adjusted EPS rose 48% yr/yr, with adjusted net income up 59%
Company completed $700 mln convertible debt offering and closed XOMA Royalty acquisition

Outlook
Ligand raises low end of 2026 adj EPS guidance to $9.00-$9.50 from $8.50-$9.50
Company maintains 2026 total revenue outlook at $270 mln to $310 mln
Company expects 2026 royalty revenue of $225 mln to $250 mln

Result Drivers
ROYALTY REVENUE GROWTH - Q2 results were driven by 32% yr/yr royalty revenue growth, mainly from Filspari, Zelsuvmi, and Ohtuvayre
CONTRACT REVENUE - Increase in contract revenue was mainly due to timing of milestone events under partner agreements
PORTFOLIO EXPANSION - XOMA acquisition added over 120 assets, further diversifying royalty base and strengthening position as a biopharma royalty aggregator

Company press release: ID:nGNX3bC3qT

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
 
$48.51 mln
 
Q2 Operating Income
 
$8.59 mln
 
Q2 Pretax Profit
 
$64.30 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ligand Pharmaceuticals Incorporated is $337.50, about 11.5% above its August 5 closing price of $302.57
The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 24 three months ago

Reuters Recommended Reads
Aug 5 - Royalty Pharma Q2 adjusted EBITDA beats estimates
Aug 4 - Travere Therapeutics Q2 product sales rise on FILSPARI demand
Aug 5 - Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)